New triple therapy targets hard-to-treat liver cancer
NCT ID NCT06882876
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 33 times
Summary
This early-phase study tests whether adding two drugs (JS014 and toripalimab) to a standard procedure called TACE can safely control liver cancer that cannot be removed by surgery. About 20 adults with unresectable hepatocellular carcinoma will receive the combination. The main goal is to check safety, and researchers will also measure tumor shrinkage and how long patients live without the cancer growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xiangya Hospital
Changsha, Hunan, China
Conditions
Explore the condition pages connected to this study.